Product category:
Chemicals and biochemicals
News Release from: Cobra Biomanufacturing
Edited by the Laboratorytalk Editorial
Team on 28 January 2008
Manufacturing agreement for TNFerade
Cobra Biomanufacturing has entered into a manufacturing development agreement with GenVec for TNFerade, GenVec's lead product candidate
The agreement will cover technology transfer, scale-up, and validation of the manufacturing process for TNFerade through cGMP consistency lots that will be produced at Cobra's facility in Oxford, United Kingdom "GenVec selected Cobra based upon their expertise in viral manufacturing and the experience of key staff members with commercial biopharmaceutical products
This article was originally published on Laboratorytalk on 11 Apr 2006 at 8.00am (UK)
Related stories
Tool for inserting genes into bacteria
Xer-cise was developed in Cobra's research laboratories over several years and enables genes to be switched in and out of bacterial chromosomal DNA cleanly and more efficiently than current methods
Akcros invests in solid stabilisers
To meet growing demand for PVC stabilisers, Akcros Chemicals will invest in increased production of the Interlite ZP range of solid mixed metal soap stabilisers at its Eccles, UK, facility
MBO for Akcros
Akzo Nobel plastics and processing additives business unit, making lead stabilisers for polymer products sold, to management, and to trade under the new name Allstab
"Activities under this agreement will establish a clear path for the submission of the chemistry, manufacturing, and controls (CMC) portion of a biological license application for TNFerade as GenVec works towards the completion of our current phase III clinical trial," said Bryan Butman, GenVec's senior vice president of vector operations.
"We are delighted to work with GenVec on this exciting project.
"TNFerade has demonstrated great potential for the treatment of pancreatic cancer," added Simon Saxby, Cobra Biomanufacturing's chief operating officer.
"This agreement will leverage Cobra's significant experience manufacturing recombinant adenovirus under cGMP conditions".
GenVec is a biopharmaceutical company developing novel therapeutic drugs and vaccines.
GenVec's lead product, TNFeradea is currently in a pivotal clinical study (Pact) in locally advanced pancreatic cancer.
Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma.
GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza.
TNFerade is an adenovector, or DNA carrier, which contains the gene for tumour necrosis factor-alpha (TNFa), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumours.
After administration, TNFerade stimulates the production of TNFa in the tumour.
GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.
• Cobra Biomanufacturing: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
